Correspondence 0001214659-23-016479 from Biodexa Pharmaceuticals Plc (BDRX)

Biodexa Pharmaceuticals Plc
Date: Dec. 15, 2023 · CIK: 0001643918 · Accession: 0001214659-23-016479

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-274895

Date

December 15, 2023

Author

Nicholas Stergis

Form

CORRESP

Company

Biodexa Pharmaceuticals Plc

Letter

Ladenburg Thalmann & Co. Inc.

640 Fifth Avenue, 4th Floor

New York, New York 10019

December 15, 2023

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, DC 20549

Re:

Biodexa Pharmaceuticals Plc

Registration Statement on Form F-1 (Registration No. 333-274895)

Concurrence in Acceleration Request

Ladies and Gentlemen:

Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Biodexa Pharmaceuticals Plc that the effective date of the above-referenced registration statement be accelerated to 5:30 p.m. (Eastern Time), or as soon as practicable thereafter, on December 18, 2023, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
LADENBURG THALMANN & CO. INC.

Show Raw Text

CORRESP
1
filename1.htm

Ladenburg Thalmann & Co. Inc.

640 Fifth Avenue, 4th Floor

New York, New York 10019

December 15, 2023

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, DC 20549

    Re:

    Biodexa Pharmaceuticals Plc

    Registration Statement on Form F-1 (Registration No. 333-274895)

    Concurrence in Acceleration Request

Ladies and Gentlemen:

Ladenburg Thalmann & Co.
Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request
by Biodexa Pharmaceuticals Plc that the effective date of the above-referenced registration statement be accelerated to 5:30 p.m. (Eastern
Time), or as soon as practicable thereafter, on December 18, 2023, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that
it is aware of its obligations under the Securities Act in connection with this offering.

    Very truly yours,

    LADENBURG THALMANN & CO. INC.

    By:
    /s/ Nicholas Stergis

    Name: Nicholas Stergis

    Title: Managing Director

SecProbe.io